Merck KGaA
Top Five Articles on 360Dx Last Week: Coverage of Cancer Tests Rescinded; FDA Clearances; and More
Last week, readers were most interested in a story about Medicare Administrative Contractor Novitas rescinding its coverage for several cancer genetic tests.
Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
The companies will develop FoundationOne Liquid CDx and FoundationOne CDx as CDx tests in the US market for selected Merck KGaA marketed and pipeline treatments.
Merck, Burning Rock Ink Liquid Biopsy Companion Diagnostics Deal
The companies intend to develop Burning Rock's 168-gene OncoCompass Target test as a companion to Merck's MET inhibitor Tepmetko in mainland China.
Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko
The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations.
Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.